{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:47:37Z","timestamp":1780080457053,"version":"3.54.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FAPERGS PPSUS","award":["1153-2551\/13-9"],"award-info":[{"award-number":["1153-2551\/13-9"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.cca.2015.11.032","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T07:45:17Z","timestamp":1449215117000},"page":"42-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia"],"prefix":"10.1016","volume":"453","author":[{"given":"Arnaud","family":"Capron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Venzon","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine Comparsi","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Su\u00f1e","family":"Mattevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Reginato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Capra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fogliatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wallemacq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-5073","authenticated-orcid":false,"given":"Rafael","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2015.11.032_bb0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia: advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2015.11.032_bb0010","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cca.2015.11.032_bb0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5581\/1516-8484.20110081","article-title":"Monitoring imatinib plasma concentrations in chronic myeloid leukemia","volume":"33","author":"Martins","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"issue":"8","key":"10.1016\/j.cca.2015.11.032_bb0020","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cca.2015.11.032_bb0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/clpt.2010.186","article-title":"Correlation between imatinib pharmacokinetics and clinic response in Japanese patients with chronic-phase chronic myeloid leukemia","volume":"88","author":"Takahashi","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.cca.2015.11.032_bb0030","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory","volume":"27","author":"Bouchet","year":"2013","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.cca.2015.11.032_bb0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"PharmacoEconomics"},{"issue":"22","key":"10.1016\/j.cca.2015.11.032_bb0040","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.cca.2015.11.032_bb0045","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.cca.2015.11.032_bb0050","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.cca.2015.11.032_bb0055","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.4155\/bio.15.101","article-title":"DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application","volume":"7","author":"Antunes","year":"2015","journal-title":"Bioanalysis"},{"issue":"1","key":"10.1016\/j.cca.2015.11.032_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083736","article-title":"Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cca.2015.11.032_bb0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/QAI.0b013e31820dc0cc","article-title":"Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting","volume":"56","author":"van Zyl","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"4","key":"10.1016\/j.cca.2015.11.032_bb0070","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/QAD.0b013e328325a4a9","article-title":"Protease inhibitor levels in hair strongly predict virologic response to treatment","volume":"23","author":"Gandhi","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.cca.2015.11.032_bb0075","unstructured":"US Department of Health and Human Services FDA, Guidance for industry. Analytical procedures and methods validation; August 2000."},{"key":"10.1016\/j.cca.2015.11.032_bb0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinbiochem.2004.11.007","article-title":"Matrix effects: the Achilles heel of quantitative high performance liquid chromatography\u2013electrospray-tandem mass spectrometry","volume":"38","author":"Taylor","year":"2005","journal-title":"Clin. Biochem."},{"issue":"6","key":"10.1016\/j.cca.2015.11.032_bb0085","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898115300693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898115300693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T02:22:31Z","timestamp":1537150951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898115300693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":17,"alternative-id":["S0009898115300693"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2015.11.032","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2015.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}